Innovent Biologics (HK:1801)
:1801
Want to see HK:1801 full AI Analyst Report?
1801 Stock Chart & Stats
HK$91.50
-HK$0.85(-2.50%)
At close: 4:00 PM EST
HK$91.50
-HK$0.85(-2.50%)
Day’s Range― - ―
52-Week RangeHK$69.55 - HK$109.10
Previous CloseN/A
Volume9.75M
Average Volume (3M)16.11M
Market Cap
HK$129.24B
Enterprise ValueHK$110.35B
Total Cash (Recent Filing)HK$18.24B
Total Debt (Recent Filing)HK$2.82B
Price to Earnings (P/E)135.2
Beta0.63
Next Earnings
Aug 26, 2026EPS Estimate
1.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.50
Shares Outstanding1,738,237,200
10 Day Avg. Volume15,175,046
30 Day Avg. Volume16,110,837
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)6.12
Price to Sales (P/S)9.09
P/FCF Ratio12.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$120.46Price Target Upside31.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)1.38
Revenue Forecast (FY)HK$18.57B
Bulls Say, Bears Say
Bulls Say
2025 Financial TurnaroundA clear 2025 inflection with revenue growth, positive net income and large free cash flow materially improves the company’s ability to fund R&D, commercial scale-up and manufacturing without relying on dilutive financing. Sustained cash profitability would de-risk the biotech growth model over the medium term.
Conservative Balance SheetRelatively low leverage and a stronger equity base give Innovent financial flexibility to invest in pipeline development and capacity expansion while withstanding clinical or commercial setbacks. Conservative debt levels reduce refinancing risk and support strategic partnerships or M&A optionality over 2–6 months and beyond.
High Gross Margins & Commercial PlatformVery high gross margins combined with in-house manufacturing and a commercialization network indicate durable unit economics for core biologics. This structural advantage supports scalable profitability as sales grow, improving returns on new launches and enabling sustainable reinvestment into the oncology and autoimmune portfolios.
Bears Say
Modest Net Margin & Profitability DurabilityAlthough 2025 shows positive net income, the net margin remains modest and the company has a multi-year history of operating losses. This raises risk that profitability is sensitive to product mix, pricing, or reimbursement shifts, and that the 2025 improvement may require repeatable execution to be durable.
Inconsistent Historical Cash FlowA sharp one-year cash flow improvement is encouraging but follows several years of negative operating and free cash flow. This inconsistency suggests some cash gains may be timing- or milestone-driven, meaning sustained self-funding of pipeline and capex depends on maintaining commercial momentum over multiple quarters.
Low Returns And Capital EfficiencyReturn metrics remain low despite improvement, indicating capital has only recently begun generating positive returns. Continued low-to-modest ROIC/ROE limits the company’s ability to convert R&D and asset base into high economic returns, creating pressure to improve margins or scale volumes to justify capital intensity.
Innovent Biologics News
1801 FAQ
What was Innovent Biologics’s price range in the past 12 months?
Innovent Biologics lowest stock price was HK$69.55 and its highest was HK$109.10 in the past 12 months.
What is Innovent Biologics’s market cap?
Innovent Biologics’s market cap is HK$129.24B.
When is Innovent Biologics’s upcoming earnings report date?
Innovent Biologics’s upcoming earnings report date is Aug 26, 2026 which is in 76 days.
How were Innovent Biologics’s earnings last quarter?
Innovent Biologics released its earnings results on Mar 26, 2026. The company reported -HK$0.012 earnings per share for the quarter, missing the consensus estimate of HK$0.139 by -HK$0.151.
Is Innovent Biologics overvalued?
According to Wall Street analysts Innovent Biologics’s price is currently Undervalued.
Does Innovent Biologics pay dividends?
Innovent Biologics does not currently pay dividends.
What is Innovent Biologics’s EPS estimate?
Innovent Biologics’s EPS estimate is 1.26.
How many shares outstanding does Innovent Biologics have?
Innovent Biologics has 1,738,237,200 shares outstanding.
What happened to Innovent Biologics’s price movement after its last earnings report?
Innovent Biologics reported an EPS of -HK$0.012 in its last earnings report, missing expectations of HK$0.139. Following the earnings report the stock price went down -3.816%.
Which hedge fund is a major shareholder of Innovent Biologics?
Currently, no hedge funds are holding shares in HK:1801
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Innovent Biologics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$120.46 (31.65% Upside)
HK$120.46 (31.65% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
101.65%
12-Months-Change
Fundamentals
Return on Equity
4.82%
Trailing 12-Months
Asset Growth
80.58%
Trailing 12-Months
Company Description
Innovent Biologics
Innovent Biologics, Inc., established in 2011 and headquartered in Suzhou, People's Republic of China, functions as a leading biopharmaceutical enterprise. The company is dedicated to the comprehensive lifecycle of antibody drug candidates, encompassing their discovery, development, and eventual manufacturing. Its therapeutic focus spans critical areas such as oncology, ophthalmology, immunology, and metabolic diseases. A key product in its portfolio is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody utilized in the treatment of various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Innovent's commercialized offerings also include Byvasda, employed for several malignant tumors; Halpryza, which addresses non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and Wegener's granulomatosis; Pemazyre, indicated for adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib, designed for adult patients facing conditions related to tyrosine kinase inhibitors; and Cyramza, approved for four distinct cancer types. The company's robust pipeline features a range of investigational therapies, such as IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein aimed at ocular fundus disease; IBI-306, a human monoclonal antibody targeting hypercholesterolemia; and IBI-310, a recombinant human anti-CTLA-4 monoclonal antibody for liver and renal cell carcinoma. Further developmental assets include IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for adults with relapsed or refractory multiple myeloma; IBI-376 for recurrent or refractory follicular lymphoma; and IBI-112 for psoriasis. Beyond drug creation, Innovent Biologics is also involved in distributing pharmaceutical products and provides expert consultation along with research and development services. The company maintains key strategic alliances with various partners, including NeoCura Bio-Medical Technology Co. Ltd., Roche Group, Ascentage Pharma Group International, Eli Lilly and Company, and Bolt Biotherapeutics, Inc.
1801 Stock 12 Month Forecast
Average Price Target
HK$120.46
▲(31.65% Upside)
Technical Analysis
3SBio
―
Akeso, Inc.
―
RemeGen Co. Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―
Options Prices
Currently, No data available
---